Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren's disease1 Ianalumab has the potential to become the first and only targeted treatment...
Hence then, the article about novartis announces both ianalumab phase iii clinical trials met primary endpoint in patients with sjogren s disease was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease )
Also on site :
- Your spend as a ‘weapon’: Scott Galloway’s ‘Resist and Unsubscribe’ movement asks you to ditch Amazon, Apple, and Netflix to oppose Trump
- Iran strikes US military base in Bahrain as explosions heard across Gulf
- Fire Country's Kevin Alejandro Teases Manny/Jake Tension After Winter Premiere — Plus, Grade The Episode!